When non-ST-elevation myocardial infarction presents in a patient with prior ischemic stroke or transient ischemic attack (TIA), this cerebrovascular history is a clinically decisive factor. It directly determines which antiplatelet agents are appropriate and which must be avoided.
This protocol applies to NSTEMI in the setting of a documented history of stroke or transient ischemic attack. This comorbidity is not incidental — it is a key driver of agent selection, as certain antiplatelet options are associated with worse net clinical outcomes in this population and must not be used.
Management is built on dual antiplatelet therapy, combining aspirin with an oral P2Y12 inhibitor to reduce major adverse cardiovascular events. However, the choice of P2Y12 inhibitor is specifically constrained by this patient's stroke or TIA history — not all available agents in this class are permitted. The full regimen, including which agents are indicated, the sequencing, and the complete clinical algorithm, is available in the structured protocol.
Full regimen, agent selection, and dosing details are behind the link below.